Derosa Giuseppe, Maffioli Pamela, D'Angelo Angela, Salvadeo Sibilla A T, Ferrari Ilaria, Fogari Elena, Gravina Alessia, Mereu Roberto, Palumbo Ilaria, Randazzo Sabrina, Cicero Arrigo F G
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Clin Invest Med. 2009 Apr 1;32(2):E124-32. doi: 10.25011/cim.v32i2.6030.
To evaluate the distribution of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and their specific inhibitors in a sample of patients affected by mild dyslipidemia but not yet treated with antihyperlipidemic drugs.
One hundred and sixty-eight Caucasian patients aged >or=18 yr of either sex with combined dyslipidemia and who had never previously taken lipid-lowering medications were evaluated. As a control population, we enrolled 179 Caucasian healthy subjects, aged >or=18 yr of either sex. We evaluated body mass index (BMI), fasting plasma glucose (FPG), fasting plasma insulin (FPI), homeostasis model assessment (HOMA index), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), lipoprotein(a) Lp(a), plasminogen activator inhibitor-1 (PAI-1), homocysteine (Hct), fibrinogen (Fg), high sensitivity C-reactive protein (Hs-CRP), adiponectin (ADP), MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 (TIMP-1), and tissue inhibitors of metalloproteinase-2 (TIMP-2).
TC, Tg, and LDL-C were higher (P < < 0.05, P < < 0.01 and P < < 0.05, respectively) in the dyslipidemic group, while HDL-C levels were lower (P < < 0.01) compared with the control group. Increases of PAI-1, Hct, Fg, and Hs-CRP (P < < 0.01, P < < 0.05, P < < 0.05, and P < < 0.05, respectively) were present in the dyslipidemic group, while ADP level was lower (P < < 0.01) in the dyslipidemic patients compared with controls. MMP-2, MMP-9, TIMP-1, and TIMP-2 levels were higher (P < < 0.0001) in the dyslipidemic group.
Combined hyperlipidemic patients have increased levels of prothrombotic and microinflammatory parameters and higher levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 than control subjects. The prognostic importance of this observation has to be evaluated in adequately designed prospective studies.
评估基质金属蛋白酶-2（MMP-2）、基质金属蛋白酶-9（MMP-9）及其特异性抑制剂在轻度血脂异常但尚未接受抗高血脂药物治疗的患者样本中的分布情况。
对168例年龄≥18岁、患有混合型血脂异常且既往从未服用过降脂药物的白种人患者进行评估。作为对照人群，我们纳入了179例年龄≥18岁的白种健康受试者。我们评估了体重指数（BMI）、空腹血糖（FPG）、空腹血浆胰岛素（FPI）、稳态模型评估（HOMA指数）、收缩压（SBP）、舒张压（DBP）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、甘油三酯（Tg）、脂蛋白（a）[Lp（a）]、纤溶酶原激活物抑制剂-1（PAI-1）、同型半胱氨酸（Hct）、纤维蛋白原（Fg）, 高敏C反应蛋白（Hs-CRP）、脂联素（ADP）、MMP-2、MMP-9、金属蛋白酶组织抑制剂-1（TIMP-1）和金属蛋白酶组织抑制剂-2（TIMP-2）。
血脂异常组的TC、Tg和LDL-C较高（分别为P << 0.05、P << 0.01和P << 0.05），而HDL-C水平与对照组相比更低（P << 0.01）。血脂异常组的PAI-1、Hct、Fg和Hs-CRP升高（分别为P << 0.01、P << 0.05、P << 0.05和P << 0.05），而血脂异常患者的ADP水平与对照组相比更低（P << 0.01）。血脂异常组的MMP-2、MMP-9、TIMP-1和TIMP-2水平更高（P << 0.0001）。
与对照组相比，混合型高脂血症患者的促血栓形成和微炎症参数水平升高，MMP-2、MMP-9、TIMP-1和TIMP-2水平更高。这一观察结果的预后重要性必须在设计充分的前瞻性研究中进行评估。
